Compare EARN & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | KRMD |
|---|---|---|
| Founded | 2012 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 177.8M |
| IPO Year | 2012 | 2019 |
| Metric | EARN | KRMD |
|---|---|---|
| Price | $4.42 | $3.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.38 | ★ $6.50 |
| AVG Volume (30 Days) | ★ 409.6K | 84.6K |
| Earning Date | 06-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $41,127,366.00 |
| Revenue This Year | $7.69 | $20.32 |
| Revenue Next Year | $19.57 | $17.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $4.27 | $2.91 |
| 52 Week High | $6.08 | $6.61 |
| Indicator | EARN | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 49.61 |
| Support Level | $4.27 | $3.82 |
| Resistance Level | $4.78 | $4.28 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 14.13 | 47.64 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.